Xeris Biopharma Holdings, Inc. (XERS) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is mixed: Seven brokerages give Xeris Biopharma a consensus “Hold” rating, with four buys, two holds, and one sell. The average 12-month price target is $13.20, while recent targets range from $14 to $16.
• Recent financial results were mixed: Xeris reported quarterly revenue of $92.1 million, exceeding expectations, but adjusted EPS of negative $0.18 missed the consensus estimate of positive $0.01. Analysts expect full-year EPS of $0.07.
• The stock has gained momentum, but insiders have been selling: Shares opened at $10.07, up 3.1%, and remain near their 12-month high of $11.33. Insiders sold 134,998 shares worth about $1.2 million over the past 90 days, while institutional investors own 42.75% of the company.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $13.20.

Several equities analysts recently weighed in on XERS shares. Barclays raised their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Weiss Ratings downgraded shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Finally, Leerink Partners increased their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research note on Thursday, September 10th.

Insider Activity at Xeris Biopharma

In related news, insider Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $141,150.00. Following the completion of the sale, the insider owned 1,599,208 shares of the company's stock, valued at approximately $15,048,547.28. The trade was a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the company's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $156,827.06. Following the completion of the sale, the insider owned 1,111,130 shares of the company's stock, valued at $10,455,733.30. This represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 134,998 shares of company stock valued at $1,202,666. Insiders own 4.35% of the company's stock.

Institutional Trading of Xeris Biopharma

Several large investors have recently made changes to their positions in the stock. GK Wealth Management LLC bought a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $32,000. Allworth Financial LP acquired a new stake in Xeris Biopharma in the 2nd quarter worth approximately $34,000. KBC Group NV acquired a new stake in Xeris Biopharma in the 1st quarter worth approximately $27,000. State of Wyoming bought a new stake in Xeris Biopharma during the second quarter worth approximately $52,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Xeris Biopharma during the second quarter worth approximately $74,000. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Trading Up 3.1%

Xeris Biopharma stock opened at $10.07 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $11.33. The company's fifty day simple moving average is $8.83 and its 200-day simple moving average is $7.61. The stock has a market cap of $1.84 billion, a P/E ratio of -91.55 and a beta of 0.53.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts' expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, sell-side analysts forecast that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.